The Latest Cardiac and Vascular News
ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with […]
World’s First Device Combining CCM Therapy With an ICD in a Single Rechargeable Implant That Treats Both Heart Failure Symptoms and Sudden Cardiac Death MARLTON, N.J., May 18, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, […]
Abbott’s Assert-IQ offers the world’s longest battery life† for an insertable cardiac monitor (ICM) The latest addition to Abbott’s portfolio of connected health devices, the Assert-IQ ICM offers long-term monitoring and remote programming to improve connectivity to patients The device provides continuous monitoring for abnormal heart rhythms while offering tools […]
Alizea™ and Celea™ are the world’s longest-lasting pacemakers for their size on the market today1 AlizeaTM and CeleaTM Pacemaker Systems feature AutoMRI™ Mode and Bluetooth®2 Connectivity May 18, 2023 08:00 AM Eastern Daylight Time CLAMART, France–(BUSINESS WIRE)–MicroPort CRM, a global pioneer in the field of Cardiac Rhythm Management, headquartered in France, announced today it […]
vMap’s use with ‘Unmappable’ Ventricular Tachycardia Ablation and Accurate Proof-of-Concept Mapping Using Outpatient 12-lead ECG Data to be Presented at the Heart Rhythm Society’s Annual Conference in New Orleans. NEW ORLEANS–(BUSINESS WIRE)–Vektor Medical, pioneers of the world’s first technology to accurately map arrhythmias using only 12-lead ECG data, today unveiled […]
Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces it has been recognized by Healthcare Tech Outlook Magazine as a 2023 […]
AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM DUBLIN, May 16, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program as the “Best […]
Not intended for UK Media The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an […]
Showed high clinical success with 86% freedom from symptomatic recurrence1 Temperature control allows for the safe use of higher RF power in short bursts, enhancing efficacy and efficiency without compromising safety1 IRVINE, Calif., May 15, 2023 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & […]
COPENHAGEN, Denmark, May 15, 2023 /PRNewswire/ — Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent […]
